Unresectable peritoneal carcinomatosis from colorectal cancer: A single center experience

Authors

  • Daphne Hompes MD,

    Corresponding author
    1. Department of Gastro-intestinal Surgery, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    • Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; Fax: 0031-20-5122549.
    Search for more papers by this author
  • Henk Boot MD, PhD,

    1. Department of Digestive Oncology, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Search for more papers by this author
  • Harm van Tinteren PhD,

    1. Department of Biostatistics, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Search for more papers by this author
  • Victor Verwaal MD, PhD

    1. Department of Surgery, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Search for more papers by this author

Abstract

Background and objectives

For unresectable peritoneal carcinomatosis (PC) median overall survival (OS) is 5–6 months. This article analyzes patients with PC from colorectal cancer (CRC) uneligible for debulking and hyperthermic intra-peritoneal chemotherapy, describing patient- and tumor-related factors possibly affecting survival.

Patients and Methods

From 2005 to 2009, 43 patients presented with unresectable PC from CRC: male/female ratio was 29/14, median age was 57.1 years (range 34.8–76.8). “Unresectability” was defined as: six to seven abdominal regions affected by PC, involvement of mesentery or small bowel in the PC, presence of liver metastases, retroperitoneal lymph nodes, vascular invasion, and/or neural invasion.

Results

Median time interval between diagnosis of the primary tumor and diagnosis of PC was 7.2 months (range 0.0–102.3). Primary tumors were right-sided in >50% and had been previously resected in >58%, 74.4% of PC occurred synchronously. Ascites was present at primary diagnosis in 37.2%. In 70% of cases, six to seven abdominal regions were affected and in 58.1% PC involved small bowel/mesentery. Systemic disease was present in 16.3%. In 18.6% of patients, a palliative diversion or ostomy was constructed.

Median OS was 6.3 months (range 0.4–33.1). Thirty-one patients (72.1%) received palliative chemotherapy. Median OS was 9.3 months (range 0.9–33.1) with versus 3.1 months (range 0.4–6.5) without chemotherapy (P = 0.000), with less favorable patient and tumor characteristics in the latter group. No other factors clearly influenced OS.

Conclusion

Palliative chemotherapy results in better OS, but this is probably attributable to factors influencing the patient's general condition. J. Surg. Oncol. 2011; 104: 269–273. © 2011 Wiley-Liss, Inc.

Ancillary